lung-cancer

Real-world SCLC data shows neutropenia during chemotherapy paradoxically links to better survival.

Analysis of 421 SCLC patients at Karolinska using Bayesian and competing risk models: neutropenia during first-line treatment associated with better OS (HR 0.70). Higher etoposide dose linked to more AEs. Dose adjustment did not affect OS if patients completed 4 cycles. Male patients had fewer AEs…

Dan Manning

Dan Manning

— 1 min read
Share
Real-world SCLC data shows neutropenia during chemotherapy paradoxically links to better survival.

Real-world SCLC data shows neutropenia during chemotherapy paradoxically links to better survival.

Analysis of 421 SCLC patients at Karolinska using Bayesian and competing risk models: neutropenia during first-line treatment associated with better OS (HR 0.70). Higher etoposide dose linked to more AEs. Dose adjustment did not affect OS if patients completed 4 cycles. Male patients had fewer AEs and better response than females. High-risk patients with early discontinuation had survival similar to untreated patients.

Key Findings

  • Neutropenia during first-line chemo paradoxically associated with better OS (HR 0.70)
  • Higher etoposide dose linked to more AEs and neutropenia
  • Dose adjustment did not affect OS if 4-cycle regimen was completed
  • Male patients had fewer AEs and better treatment response than females
  • High-risk patients with early discontinuation had survival similar to no treatment

Implications

SCLC first-line therapy may benefit from individualized dosing. Risk-benefit should be carefully weighed for elderly/poor-performance patients.

Caveats

Retrospective single-center (n=421); abstract-only. Swedish academic center may not represent broader population.

Source: JMIR cancer — 2026-04-10

Read more